natgillin/translations-raw huggingface dataset:
cancel the fresh embryo transfer and cryopreserve embryos; avoid administration of hCG for luteal phase support.
otkazivanje prijenosa svježeg embrija i krioprezervacija embrija; izbjegavanje primjene hCG-a za potporu lutealne faze.
cancer
karcinom
cancer (except basal-cell carcinoma, a slow-growing type of skin cancer) or severe impairment of the heart function
karcinom (osim bazocelularnog karcinoma, vrste sporo napredujućeg karcinoma kože) ili teško oštećenje funkcije srca
cancer (second primary malignancies)
rak (druga primarna zloćudna bolest)
cancer (such as erlotinib, gefitinib). stomach disease or heartburn (antacids such as aluminium hydroxide/magnesium hydroxide).
raka (kao što su erlotinib, gefitinib). želučane bolesti ili žgaravice (antacidi kao što su aluminijev hidroksid/magnezijev hidroksid).
Cancer cells are more sensitive to disruption by proteasome inhibitors than normal cells and, therefore, to the effects of bortezomib.
Stanice raka su osjetljivije na poremećaj inhibitora proteazoma u odnosu na normalne stanice i, stoga, na djelovanje bortezomiba.
Cancer cells can produce proteins (PD-L1 and PD-L2) that attach to this receptor and switch off the activity of the T cells, preventing them from attacking the cancer.
Stanice raka mogu proizvesti bjelančevine (PD-L1 i PD-L2) koje se vežu uz taj receptor i gase aktivnost T stanica, tako ih sprečavajući da napadaju rak.
Cancer cells have an increased need to produce and break down proteins due to the fact that they are multiplying rapidly.
Stanice raka imaju povećanu potrebu stvaranja i razgradnje bjelančevina zbog činjenice da se brzo umnožavaju.
cancer in your ovaries, womb or breasts.
rak jajnika, maternice ili dojke.
cancer of the blood (leukaemia);
rak krvi (leukemija);
cancer of the blood cells (leukaemia)
rak krvnih stanica (leukemiju)
cancer of the bone marrow (multiple myeloma)
rak koštane srži (multipli mijelom)
cancer of the colon or rectum (large intestine) that is metastatic (has spread to other parts of the body), in combination with chemotherapy medicines that include a ‘fluoropyrimidine’;
metastatskim (koji se proširio na druge dijelove tijela) rakom debelog crijeva ili rektuma, u kombinaciji s kemoterapijom na bazi „fluoropirimidina”;
Cancer of the kidney
karcinom bubrega
cancer of the kidney
rak bubrega
cancer of the lymph nodes (lymphoma) (rare).
rak limfnih čvorova (limfom) (rijetko).
Cancer of the lymph tissue (lymphoma/post-transplant lympho-proliferative disorder), combined lowering of red blood cells, white blood cells and blood platelets
rak limfnog tkiva (limfom/posttransplantacijski limfoproliferativni poremećaj), kombinirano sniženje broja crvenih krvnih stanica, bijelih krvnih stanica i krvnih pločica
cancer of the rectum
rak debelog crijeva
Cancer of the skin
karcinom kože
cancer of the skin
rak kože
cancer of white blood cells, lung cancer throat tightness
rak bijelih krvnih stanica, rak pluća stezanje u grlu
cancer of white blood cells, lung cancer throat tightness.
rak bijelih krvnih stanica, rak pluća stezanje u grlu
Cancer pain
Bol povezana s rakom
Cancer pain
Maligna bol
Cancer patients
Bolesnici s karcinomom
Cancer patients
Bolesnici s malignom bolešću
Cancer patients
Onkološki bolesnici
Cancer patients are more likely to suffer from blood clots if receiving erythropoietin medicines, like Retacrit (see section 4).
Bolesnici s rakom imaju veću šansu za stvaranje krvnih ugrušaka ukoliko primaju lijekove s eritropoetinom poput Retacrita (pogledajte dio 4).
Cancer patients are more likely to suffer from blood clots if receiving erythropoietin medicines, like Silapo (see section 4).
Bolesnici s rakom imaju veći šansu za stvaranje krvnih ugrušaka ukoliko primaju lijekove s eritropoetinom poput Silapa (vidjeti odjeljak 4).
Cancer patients on erythropoietin should have haemoglobin (the part of a red blood cell that carries oxygen) levels measured on a regular basis until a stable level is achieved, and periodically thereafter.
Kod bolesnika s rakom koji primaju eritropoetin, treba redovito mjeriti razinu hemoglobina (dio crvenih krvnih stanica koji nosi kisik) sve dok se ne postigne stabilna razina, a zatim povremeno.
cancer that affects the lymph system
rak koji zahvaća limfni sustav
cancer that affects the lymph system;
rak koji zahvaća limfni sustav,
cancer treatments
lijekove protiv raka
Cancer Type
Sijelo
cancer, chemotherapy, radiotherapy, corticosteroids, angiogenesis inhibitors, smoking a history of dental disease, poor oral hygiene, periodontal disease, invasive dental procedures and poorly fitting dentures
karcinom, kemoterapija, radioterapija, kortikosteroidi, inhibitori angiogeneze, pušenje anamneza bolesti zuba, loša oralna higijena, bolesti parodonta, invazivni stomatološki zahvati i neodgovarajući zubni nadomjestak.
cancer, chemotherapy, radiotherapy, corticosteroids, angiogenesis inhibitors, smoking a history of dental disease, poor oral hygiene, periodontal disease, invasive dental procedures and poorly fitting dentures
rak, kemoterapija, radioterapija, kortikosteroidi, inhibitori angiogeneze, pušenje anamneza bolesti zuba, loša oralna higijena, bolesti parodonta, invazivni stomatološki zahvati i neodgovarajuće zubne proteze.
cancer, chemotherapy, radiotherapy, corticosteroids, angiogenesis inhibitors, smoking a history of dental disease, poor oral hygiene, periodontal disease, invasive dental procedures and poorly fitting dentures
rak, kemoterapija, radioterapija, kortikosteroidi, inhibitori angiogeneze, pušenje anamneza bolesti zuba, loša oralna higijena, bolesti parodonta, invazivni stomatološki zahvati i neodgovarajući zubni nadomjestak.
cancer, chemotherapy, radiotherapy, corticosteroids, angiogenesis inhibitors, smoking a history of dental disease, poor oral hygiene, periodontal disease, invasive dental procedures, and poorly fitting dentures
karcinom, kemoterapija, radioterapija, kortikosteroidi, inhibitori angiogeneze, pušenje anamneza bolesti zuba, loša oralna higijena, bolesti parodonta, invazivni stomatološki zahvati i neodgovarajući zubni nadomjestak.
cancer, chemotherapy, radiotherapy, corticosteroids, angiogenesis inhibitors, smoking a history of dental disease, poor oral hygiene, periodontal disease, invasive dental procedures, and poorly fitting dentures
rak, kemoterapija, radioterapija, kortikosteroidi, inhibitori angiogeneze, pušenje anamneza bolesti zuba, loša oralna higijena, bolesti parodonta, invazivni stomatološki zahvati i neodgovarajući zubni nadomjestak.
Cancer, co morbid conditions (e.g. anaemia, coagulopathies, infection), smoking.
Rak, komorbiditetna stanja (npr. anemija, koagulopatije, infekcija), pušenje.
Cancer, co-morbid conditions (e.g. anaemia, coagulopathies, infection), smoking
rak, popratna stanja (npr. anemija, koagulopatije, infekcija), pušenje
Cancer, co-morbid conditions (e.g. anaemia, coagulopathies, infection), smoking.
rak, komorbiditetna stanja (npr. anemija, koagulopatije, infekcija), pušenje
Cancer, co-morbid conditions (e.g. anaemia, coagulopathies, infection), smoking.
Rak, komorbiditetna stanja (npr. anemija, koagulopatije, infekcija), pušenje .
Cancer, co-morbid conditions (e.g. anaemia, coagulopathies, infection), smoking.
Rak, komorbiditetna stanja (npr. anemija, koagulopatije, infekcija), pušenje.
Cancer, co-morbid conditions (e.g. anaemia, coagulopathies, infection), smoking.
rak, komorbidna stanja (npr. anemija, koagulopatije, infekcija), pušenje.
Cancer, co-morbid conditions (e.g. anaemia, coagulopathies, infection), smoking.
rak, popratna stanja (npr. anemija, koagulopatije, infekcija), pušenje
Cancer, systemic lupus erythematosus, haemolytic uraemic syndrome, chronic inflammatory bowel disease (Crohn's disease or ulcerative colitis) and sickle cell disease
Rak, sistemski lupus eritematosus, hemolitičko- uremijski sindrom, kronična upalna bolest crijeva (Crohnova bolest ili ulcerozni kolitis) i anemija srpastih stanica.
Cancer, systemic lupus erythematosus, haemolytic uraemic syndrome, chronic inflammatory bowel disease (Crohn's disease or ulcerative colitis) and sickle cell disease.
Karcinom, sistemski lupus eritematodes, hemolitičko- uremijski sindrom, kronična upalna bolest crijeva (Crohnova bolest ili ulcerozni kolitis) i anemija srpastih stanica.
Cancer-related pain
Bol uzrokovana rakom
Cancer.
raka
Cancer: Tell your doctor if the child has or has ever had lymphoma (a type of blood cancer) or any other cancer before the child is given Enbrel.
Rak: prije nego započnete liječenje Enbrelom obavijestite svog liječnika ako dijete ima ili je ikad imalo limfom (vrsta raka krvi) ili bilo koji drugi rak.
Cancer: Tell your doctor if you have or have ever had lymphoma (a type of blood cancer) or any other cancer before you are given Benepali.
Rak: Prije nego započnete liječenje Benepalijem obavijestite svog liječnika ako imate ili ste ikad imali limfom (vrsta raka krvi) ili bilo koji drugi rak.
Cancer: Tell your doctor if you have or have ever had lymphoma (a type of blood cancer) or any other cancer before you are given Enbrel.
Rak: prije nego započnete liječenje Enbrelom obavijestite svog liječnika ako imate ili ste ikad imali limfom (vrsta raka krvi) ili bilo koji drugi rak.
cancer;
rak,
Cancerous white blood cells at or near the injection site (plasmacytoma).
Tumorske bijele krvne stanice na mjestu ili blizu mjesta injiciranja (plazmocitom).
Cancers were reported in treatment-experienced and treatment-naïve patients who initiated ISENTRESS in conjunction with other antiretroviral agents.
U prethodno liječenih i još neliječenih bolesnika, koji su započeli liječenje lijekom ISENTRESS u kombinaciji s drugim antiretrovirusnim lijekovima, prijavljeni su slučajevi raka.
Cancers, including skin cancer and non-cancerous growths or lumps, including skin moles
karcinomi, uključujući rak kože i nekancerogene izrasline ili kvržice, uključujući madeže
CANCIDAS added to
CANCIDAS dodan u
CANCIDAS added to
završna koncentracija
Cancidas contains a medicine called caspofungin.
Cancidas sadrži lijek koji se zove kaspofungin.
CANCIDAS for
lijeka
Cancidas has not been studied in pregnant women.
Cancidas nije ispitan u trudnica.
Cancidas is a sterile, white to off-white compact powder.
Cancidas je sterilni, bijeli do bjelkasti kompaktni prašak.
CANCIDAS is formulated to provide the full labeled vial dose (50 mg) when 10 ml is withdrawn from the vial.
CANCIDAS je pripravljen tako da se izvlačenjem 10 ml iz bočice sigurno dobije puna doza navedena na naljepnici bočice (50 mg).
CANCIDAS is formulated to provide the full labelled vial dose (70 mg) when 10 ml is withdrawn from the vial.
CANCIDAS je pripravljen tako da se izvlačenjem 10 ml iz bočice sigurno dobije puna doza navedena na naljepnici bočice (70 mg).
Cancidas is used to treat the following infections in children, adolescents and adults: serious fungal infections in your tissues or organs (called ‘invasive candidiasis’).
Cancidas se koristi za liječenje sljedećih infekcija u djece, adolescenata i odraslih: ozbiljne gljivične infekcije u tkivima ili organima (nazvane „invazivna kandidijaza“).
CANCIDAS), or any of the other ingredients of this medicine (listed in section 6).
CANCIDAS) ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.).
Candesartan
kandesartan
Candida albicans: S ≤0.06 mg/L, R >0.06 mg/L
Candida albicans: S ≤0,06 mg/l, R >0,06 mg/l
Candida infections in the oropharynx
Kandidijaza orofarinksa
Candida parapsilosis: S ≤0.06 mg/L, R >0.06 mg/L
Candida parapsilosis: S ≤0,06 mg/l, R >0,06 mg/l
Candida tropicalis: S ≤0.06 mg/L, R >0.06 mg/L
Candida tropicalis: S ≤0,06 mg/l, R >0,06 mg/l
Candidaemia and other forms of Invasive Candidiasis
Kandidemija i drugi oblici invazivne kandidijaze
Candidaemia only
Samo kandidemija
Candidiasis
kandidijaza
Candidiasis (including oral and anal candidiasis) and fungal infection/fungal skin infections
kandidijaza (uključujući oralnu i analnu kandidijazu) i gljivične infekcije/gljivične infekcije kože
Candidiasis including oropharyngeal and vulvovaginal, Clostridium difficile colitis, fungal urinary tract infection
kandidijaza uključujući orofaringealnu i vulvovaginalnu kandidijazu, kolitis uzrokovan bakterijom Clostridium difficile, gljivične infekcije mokraćnog sustava
Candidiasis of mouth and throat
kandidijaza usne šupljine i grla
candidiasis, staphylococcal infection
kandidijaza, stafilokokna infekcija
Cangrelor (N=12565)
Kangrelor (N= 12 565)
Cangrelor (N=5529)
Kangrelor (N= 5529)
Cangrelor exhibits inhibition of activation and aggregation of platelets as shown by aggregometry (light transmission and impedance), point-of care assays, such as the VerifyNow P2Y12™ test, VASP-P and flow cytometry.
Kangrelor inhibira aktivaciju i agregaciju trombocita kako pokazuju agregometrija (propusnost svjetla i impedancija), pretrage uz bolesnika (engl. point-of care assays), primjerice VerifyNow P2Y12™ test, VASP-P i protočna citometrija.
Cangrelor has not been evaluated in a paediatric population (see section 4.2 and section 5.1).
Kangrelor nije ispitivan u pedijatrijskoj populaciji (vidjeti dio 4.2 i dio 5.1).
Cangrelor is contraindicated in patients with any history of stroke/TIA, (see section 4.3 and section 4.8).
Kangrelor je kontraindiciran u bolesnika s bilo kakvom anamnezom moždanog udara/TIA (vidjeti dio 4.3 i dio 4.8).
Cangrelor is deactivated rapidly in the plasma by dephosphorylation to form its primary metabolite, a nucleoside.
Kangrelor se brzo deaktivira u plazmi defosforilacijom, čime se stvara njegov primarni metabolit, nukleozid.
Cangrelor N=5462
kangrelor N= 5462
Cangrelor N=5470
kangrelor N= 5470
Cangrelor produced dose-related foetal growth retardation characterised by increased incidences of incomplete ossification and unossified hind limb metatarsals in rats.
Kangrelor je izazvao zastoj u fetalnom rastu povezan s dozom koji je bio karakteriziran povećanim incidencijama nepotpune osifikacije i neosificiranih metatarzalnih dijelova stražnjih nogu u štakora.
Canigen L4 Suspension for injection for dogs
Canigen L4, suspenzija za injekciju za pse
Canigen L4, suspension for injection for dogs
Canigen L4, suspenzija za injekciju za pse
canine adenovirus type 1, which causes an acute liver infection that may produce signs of jaundice (yellowing of the skin and eyes);
psećeg adenovirusa tipa 1 koji uzrokuje akutnu infekciju jetre koja može uzrokovati znakove žutice (žućenje kože i očiju)
Canine adenovirus type 2
Pseći adenovirus tip 2
canine adenovirus, which causes an acute liver infection that may produce signs of jaundice (yellowing of the skin and eyes);
psećeg adenovirusa koji uzrokuje akutnu infekciju jetre koja može uzrokovati znakove žutice (žućenje kože i očiju)
Canine distemper virus
Virus štenećaka,
canine distemper, an infectious disease which is sometimes called hard pad since dogs can develop thickening of the skin on the foot pads, as well as runny nose, cough, fever, vomiting and diarrhoea, excessive salivation and in some cases fits;
štenećaka, infektivne bolesti koja se ponekad naziva i bolest tvrdih mekuši jer psi mogu razviti zadebljanje kože na jastučićima šapa kao i curenje iz nosa, kašalj, vrućicu, povraćanje i proljev, prekomjerno slinjenje i u nekim slučajevima napadaje
canine distemper, an infectious disease which is sometimes called ‘hard pad’ since dogs can develop thickening of the skin on the foot pads, as well as runny nose, cough, fever, vomiting, diarrhoea, excessive salivation and in some cases fits;
štenećaka, infektivne bolesti koja se ponekad naziva i bolest tvrdih mekuši jer psi mogu razviti zadebljanje kože na jastučićima šapa kao i curenje iz nosa, kašalj, vrućicu, povraćanje i proljev, prekomjerno slinjenje i u nekim slučajevima napadaje
Canine parainfluenza Type 2 virus, strain CPiV Bio 15
Pseći parainfluenca virus tip 2, soj CPiV Bio 15
Canine parainfluenza Type 2 virus, strain CPiV-2 Bio 15
Pseći parainfluenca virus tip 2, soj CPiV-2-Bio 15
Canine parainfluenza type 2 virus, strain CPiV-2 Bio 15 103.1 - 105.1 TCID50*/ml
Pseći parainfluenca virus tip 2, soj CPiV-2-Bio 15 103,1 -105,1 TCID50/ml
Canine parainfluenza type 2 virus, strain CPiV-2 Bio 15 103.1 - 105.1 TCID50*/ml
Pseći parainfluenca virus tip 2, soj CPiV-2-Bio 15103,1 -05,1 TCID50
Canine parainfluenza type 2 virus, strain CPiV-2 Bio 15 103.1 _ 105.1 TCID50*/ml Canine adenovirus type 2, strain CAV-2 Bio 13 103.6 – 105.3 TCID50*/ml Canine parvovirus type 2b, strain CPV-2b Bio 12/B 104.3 – 106.6 TCID50*/ml Canine parainfluenza type 2 virus, strain CPiV-2 Bio 15 103.1 – 105.1 TCID50*/ml
Virus štenećaka, soj CDV Bio 11/ 103.1 -105.1TCID50* Pseći adenovirus tip 2, soj CAV-2-Bio 13 103.6 -105.3TCID50* Pseći parvovirus tip 2b, soj CPV-2b-Bio 12/B 104.3 -106.6TCID50* Pseći parainfluenca virus tip 2, soj CpiV-Bio 15 103.1 -105.1TCID50
Canine parainfluenza Type 2 virus, strain CPiV-2 Bio 15 103.1 TCID50* 105.1 TCID50
Pseći parainfluenca virus, tip 2, soj CPiV-2 Bio 15 103,1 TCID50* 105,1 TCID50
Canine parainfluenza Type 2 virus, strain CPiV-2 Bio 15 103.1 TCID50* 105.1 TCID50*
Pseći parainfluenca virus tip 2, soj CPiV-2 Bio 15 103,1 TCID50* 105,1 TCID50
Canine parainfluenza type 2 virus, strain CPiV-2 Bio 15 103.1 – 105.1 TCID50*/ml
Pseći parainfluenca virus tip 2, soj CPiV-2-Bio 15 103,1 -105,1 TCID50
Canine parainfluenza virus type 2
Pseći parainfluenca virus tip 2
Canine parainfluenza virus Type 2 10 3.1 TCID50 105.1 TCID50
Pseći parainfluenca virus tip 2 103,1 TCID50* 105,1 TCID50
canine parainfluenza virus, which causes kennel cough;
virusa pseće parainfluence, koji uzrokuje kašalj čopora;
canine parainfluenza virus, which causes kennel cough; leptospirosis, a bacterial disease that may be transmitted via infected urine and result in bleeding, hepatitis (inflammation of the liver) and jaundice or nephritis (kidney inflammation).
virusa pseće parainfluence, koji uzrokuje kašalj čopora; leptospiroze, bakterijske bolesti koja se može prenijeti putem zaraženog urina, a rezultira krvarenjem, hepatitisom (upalom jetre) i žuticom ili nefritisom (upalom bubrega);
canine parvovirus disease, an infection that may severely affect puppies, resulting in lethargy, fever, vomiting and bloody diarrhoea; canine parainfluenza virus and canine adenovirus type 2, which cause kennel cough.
infekcije psećim parvovirusom koja može teško utjecati na štence, što uzrokuje letargiju, vrućicu, povraćanje i krvavi proljev virusa pseće parainfluence i psećeg adenovirusa tipa 2 koji uzrokuju zarazni traheobronhitis (kašalj čopora).
canine parvovirus disease, an infection that may severely affect puppies, resulting in lethargy, fever, vomiting and bloody diarrhoea; canine parainfluenza virus, the cause of kennel cough;
infekcije psećim parvovirusom koja može teško utjecati na štence, što uzrokuje letargiju, vrućicu, povraćanje i krvavi proljev virusa pseće parainfluence koji uzrokoje zarazni traheobronhitis (kašalj čopora)
cannot keep food or water in your body because of severe nausea and vomiting
ne možete zadržati hranu ili vodu u vašem tijelu usljed jake mučnine ili povraćanja
Can’t be sold separately.
Ne može se prodavati odvojeno.
Can’t be sold separately.
Ne može se prodavati zasebno.
Can’t be sold separately.
Ne smije se zasebno prodavati.
Cap
Zatvara č
Cap
Zatvarač
Cap Clip
Kvačica na zatvaraču
Cap Inspection window Internal needle cover
Poklopac Prozorčić za provjeru Zaklopac unutarnje igle
Cap: light blue opaque printed ‘M’ axially in black ink.
Kapica: neprozirna, svijetloplava s oznakom ‘M’ uzdužno otisnutom crnom tintom..
Cap: Protective cap is on the dual vial unit.
Zatvarač: zaštitni zatvarač se nalazi na jedinici s dvostrukom bočicom.
Capecitabine (2,500 mg/m2/day, days 1-14 q21 days)
Kapecitabin (2500 mg/m2/dan, 1.-14. dan, ciklus od 21 dan)
Capecitabine Accord
Kapecitabin Accord
Capecitabine Accord 150 mg film-coated tablets
Kapecitabin Accord 150 mg filmom obložene tablete
Capecitabine Accord 150 mg film-coated tablets are light peach coloured, oblong shaped, biconvex, film-coated tablets of 11.4 mm in length and 5.3 mm in width, debossed with ‘150’ on one side and plain on other side.
Kapecitabin Accord 150 mg filmom obložene tablete su svijetle boje breskve, duguljaste, bikonveksne filmom obložene tablete, duljine 11,4 mm i širine 5,3 mm s utisnutom oznakom „150“ na jednoj i bez oznake na drugoj strani.
Capecitabine Accord 300 mg film-coated tablets
Kapecitabin Accord 300 mg filmom obložene tablete.
Capecitabine Accord 300 mg film-coated tablets are white to off white, oblong shaped, biconvex, film-coated tablets of 14.6 mm in length and 6.7 mm in width, debossed with ‘300’ on one side and plain on other side.
Kapecitabin Accord 300 mg filmom obložene tablete su bijele do gotovo bijele boje, duguljaste, bikonveksne filmom obložene tablete, duljine 14,6 mm i širine 6,7 mm s utisnutom oznakom „300“ na jednoj i bez oznake na drugoj strani.
Capecitabine Accord 500 mg film-coated tablets
Kapecitabin Accord 500 mg filmom obložene tablete
Capecitabine Accord 500 mg film-coated tablets are peach coloured, oblong shaped, biconvex, film-coated tablets of 15.9 mm in length and 8.4 mm in width, debossed with ‘500’ on one side and plain on other side.
Kapecitabin Accord 500 mg filmom obložene tablete su boje breskve, duguljaste, bikonveksne filmom obložene tablete, duljine 15,9 mm i širine 8.4 mm s utisnutom oznakom „500“ na jednoj i bez oznake na drugoj strani.
Capecitabine Accord dose calculations
Izračuni doze Kapecitabina Accord
Capecitabine Accord is available in blister packs (Aluminium/Aluminium or PVC/PVdC/Aluminium) containing 30, 60 or 120 film-coated tablets or in perforated unit dose blister packs (PVC/PVDC/Aluminium) containing 30 x 1, 60 x 1 or 120 x 1 film-coated tablets.
Kapecitabin Accord je dostupan u blister pakiranjima (aluminij/aluminij ili PVC/PVdC/aluminij) koja sadrže 30, 60 ili 120 filmom obloženih tableta ili perforiranim blisterima (PVC/PVDC/aluminij) djeljivim na jedinične doze koji sadrže 30 x 1, 60 x 1 ili 120 x 1 filmom obloženih tableta.
Capecitabine Accord should only be prescribed by a qualified physician experienced in the utilisation of anti-neoplastic medicinal products.
Kapecitabin Accord može propisati samo liječnik specijalist s iskustvom u primjeni antineoplastičnih lijekova.
Capecitabine Accord tablets should be swallowed with water within 30 minutes after a meal.
Kapecitabin Accord filmom obložene tablete moraju se progutati s vodom unutar 30 minuta nakon obroka.
Capecitabine can induce severe skin reactions such as Stevens-Johnson syndrome and Toxic Epidermal Necrolysis.
Kapecitabin Accord može potaknuti razvoj teških kožnih reakcija poput Stevens-Johnosonova sindroma i toksične epidermalne nekrolize.
Capecitabine can induce severe skin reactions such as Stevens-Johnson syndrome and Toxic Epidermal Necrolysis.
Kapecitabin može potaknuti razvoj teških kožnih reakcija poput Stevens- Johnosonova sindroma i toksične epidermalne nekrolize.
Capecitabine can induce the occurrence of diarrhoea, which has been observed in up to 50% of patients.
U do 50% bolesnika je uočeno da kapecitabin može inducirati pojavu proljeva.
Capecitabine dose reduction decreases systemic exposure to 5-FU more than dose- proportionally, due to non-linear pharmacokinetics for the active metabolite.
Smanjenje doze kapecitabina smanjuje sistemnu izloženost 5-FU-u više nego proporcionalno dozi, zbog nelinearne farmakokinetike aktivnoga metabolita.
Capecitabine is a ‘prodrug’ that is converted to 5-fluorouracil (5-FU) in the body, but more is converted in tumour cells than in normal tissues.
Kapecitabin je prolijek koji se u tijelu pretvara u 5-fluorouracil (5-FU), i to u većoj mjeri u stanicama tumora nego u zdravom tkivu.
Capecitabine is a ‘prodrug’ that is converted to 5-fluorouracil (5-FU) in the body, mainly in tumour cells.
Kapecitabin je predlijek koji se u tijelu pretvara u 5-fluorouracil (5-FU), i to uglavnom u stanicama tumora.
Capecitabine is contraindicated in patients with severe renal impairment (creatinine clearance below 30 ml/min [Cockcroft and Gault] at baseline).
Primjena kapecitabina je kontraindicirana u bolesnika s teškim oštećenjem bubrežne funkcije (početni klirens kreatinina manji od 30 ml/min [prema Cockroft Gaultovoj formuli]).